| Primary |
| Diabetic Neuropathy |
100.0% |
|
|
| Secondary |
| Drug Use For Unknown Indication |
58.8% |
| Hypothyroidism |
11.8% |
| Blood Triglycerides Increased |
5.9% |
| Convulsion |
5.9% |
| High Density Lipoprotein Decreased |
5.9% |
| Low Density Lipoprotein Increased |
5.9% |
| Product Used For Unknown Indication |
5.9% |
|
| Skin Discolouration |
40.0% |
| Anticonvulsant Drug Level Below Therapeutic |
20.0% |
| Drug Hypersensitivity |
20.0% |
| Somnolence |
20.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.5% |
| Drug Use For Unknown Indication |
19.9% |
| Hypertension |
3.6% |
| Pain |
3.3% |
| Rheumatoid Arthritis |
3.3% |
| Asthma |
2.7% |
| Depression |
2.6% |
| Blood Cholesterol Increased |
2.4% |
| Gastrooesophageal Reflux Disease |
2.4% |
| Diabetes Mellitus |
2.4% |
| Type 2 Diabetes Mellitus |
2.1% |
| Vitamin Supplementation |
2.1% |
| Multiple Sclerosis |
1.9% |
| Neuropathy Peripheral |
1.8% |
| Prophylaxis |
1.8% |
| Post Laminectomy Syndrome |
1.5% |
| Hypothyroidism |
1.3% |
| Anxiety |
1.2% |
| Nausea |
1.1% |
| Atrial Fibrillation |
1.1% |
|
| Vomiting |
14.4% |
| White Blood Cell Count Increased |
12.2% |
| Weight Increased |
7.9% |
| Flushing |
7.2% |
| Drug Ineffective |
6.5% |
| Pain In Extremity |
5.8% |
| Weight Decreased |
5.0% |
| Rash |
4.3% |
| Thrombocytopenia |
4.3% |
| Visual Impairment |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Pneumonia |
3.6% |
| Pain |
2.9% |
| Pruritus |
2.9% |
| Thermal Burn |
2.9% |
| Tremor |
2.9% |
| Dyspnoea |
2.2% |
| Fatigue |
2.2% |
| Headache |
2.2% |
| Hypersomnia |
2.2% |
|
| Interacting |
| Pulmonary Embolism |
100.0% |
|
| Drug Interaction |
50.0% |
| International Normalised Ratio Abnormal |
50.0% |
|
